Selected article for: "prevention vaccine development and vaccine development"
Author: Shereen, Muhammad Adnan; Khan, Suliman; Kazmi, Abeer; Bashir, Nadia; Siddique, Rabeea
Title: COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses
  • Document date: 2020_3_16
    • ID: 1mjaycee_16
    Snippet: There is no available vaccine against COVID-19, while previous vaccines or strategies used to develop a vaccine against SARS-CoV can be effective. Recombinant protein from the Urbani (AY278741) strain of SARS-CoV was administered to mice and hamsters, resulted in the production of neutralizing antibodies and protection against SARS-CoV [56, 57] . The DNA fragment, inactivated whole virus or live-vectored strain of SARS-CoV (AY278741), significant.....
    Document: There is no available vaccine against COVID-19, while previous vaccines or strategies used to develop a vaccine against SARS-CoV can be effective. Recombinant protein from the Urbani (AY278741) strain of SARS-CoV was administered to mice and hamsters, resulted in the production of neutralizing antibodies and protection against SARS-CoV [56, 57] . The DNA fragment, inactivated whole virus or live-vectored strain of SARS-CoV (AY278741), significantly reduced the viral infection in various animal models [58] [59] [60] [61] [62] [63] . Different other strains of SARS-CoV were also used to produce inactivated or live-vectored vaccines which efficiently reduced the viral load in animal models. These strains include, Tor2 (AY274119) [64, 65] , Utah (AY714217) [66] , FRA (AY310120) [59] , HKU-39849 (AY278491) [57, 67] , BJ01 (AY278488) [68, 69] , NS1 (AY508724) [70] , ZJ01 (AY297028) [70] , GD01 (AY278489) [69] and GZ50 (AY304495) [71] . However, there are few vaccines in the pipeline against SARS-CoV-2. The mRNA based vaccine prepared by the US National Institute of Allergy and Infectious Diseases against SARS-CoV-2 is under phase 1 trial [72] . INO-4800-DNA based vaccine will be soon available for human testing [73] . Chinese Centre for Disease Control and Prevention (CDC) working on the development of an inactivated virus vaccine [74, 75] . Soon mRNA based vaccine's sample (prepared by Stermirna Therapeutics) will be available [76] . GeoVax-BravoVax is working to develop a Modified Vaccina Ankara (MVA) based vaccine [77] . While Clover Biopharmaceuticals is developing a recombinant 2019-nCoV S protein subunit-trimer based vaccine [78] .

    Search related documents:
    Co phrase search for related documents
    • animal model and different SARS CoV strain: 1
    • animal model and hamster mouse: 1, 2, 3, 4
    • animal model and human testing: 1, 2
    • animal model and previous vaccine: 1
    • animal model and recombinant protein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • available vaccine and base vaccine: 1, 2, 3
    • available vaccine and human testing: 1
    • available vaccine and neutralize antibody: 1
    • available vaccine and previous vaccine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
    • available vaccine and recombinant protein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • base vaccine and previous vaccine: 1
    • base vaccine and recombinant protein: 1, 2
    • dna fragment and recombinant protein: 1, 2, 3, 4
    • hamster mouse and recombinant protein: 1
    • human testing and recombinant protein: 1, 2, 3
    • neutralize antibody and previous vaccine: 1, 2